News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Posard Matthew L.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
| 06/12/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Talis Biomedical Corp|
Txns:
| Granted 95,000 options to buy
@ $0.5, valued at
$47.5k
|
|
| 06/05/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on DermTech, Inc.|
Txns:
| Granted 35,714 shares
@ $0 |
|
| 05/09/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,065 shares
@ $0
Granted 11,371 options to buy
@ $31, valued at
$352.5k
|
|
| 12/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Talis Biomedical Corp|
Txns:
| Granted 95,000 options to buy
@ $1, valued at
$95k
|
|
| 05/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/01/2021 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.|
Txns:
| Bought 20,000 shares
@ $4.57, valued at
$91.4k
Bought 10,000 shares
@ $4.5, valued at
$45k
Bought 10,000 shares
@ $4.4612, valued at
$44.6k
Bought 10,000 shares
@ $4.4493, valued at
$44.5k
|
|
| 06/09/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/19/2021 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Talis Biomedical Corp|
Txns:
| Bought 62,500 shares
@ $16, valued at
$1M
|
|
| 02/11/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2020 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS, INC.|
Txns:
| Granted 8,829 restricted stock units
@ $0 |
|
| 05/01/2020 |
4
| Posard Matthew L. (Director) has filed a Form 4 on DermTech, Inc.|
Txns:
| Exercised 9,702 options to buy
@ $6.94, valued at
$67.3k
|
|
| 02/03/2020 |
4
| Posard Matthew L. (Director) has filed a Form 4 on DermTech, Inc.|
Txns:
| Granted 6,000 shares
@ $0 |
|
| 01/03/2020 |
4
| Posard Matthew L. (Director) has filed a Form 4 on DermTech, Inc.|
Txns:
| Exercised 15,994 restricted stock units
@ $0 |
|
| 09/09/2019 |
3
| Posard Matthew L. (Director) has filed a Form 3 on DermTech, Inc. |
| 05/03/2019 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Granted 12,173 shares
@ $0 |
|
| 05/02/2018 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Granted 10,363 shares
@ $0 |
|
| 05/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/06/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/28/2013 |
4
| Posard Matthew L. (Director) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Granted 20,000 shares
@ $0 |
|
| 03/28/2013 |
3
| Posard Matthew L. (Director) has filed a Form 3 on HALOZYME THERAPEUTICS INC |
| 03/12/2013 |
4
| Posard Matthew L. (Sr VP & General Manager) has filed a Form 4 on ILLUMINA INC|
Txns:
| Paid exercise price by delivering 685 shares
@ $53.77, valued at
$36.8k
Paid exercise price by delivering 939 shares
@ $53.77, valued at
$50.5k
|
|
| 03/12/2012 |
4
| Posard Matthew L. (Sr VP & GM, Consumer Genomics) has filed a Form 4 on ILLUMINA INC|
Txns:
| Granted 5,000 shares
@ $0
Granted 7,292 shares
@ $0
Granted 32,813 options to buy
@ $0 |
|
| 03/07/2012 |
3
| Posard Matthew L. (Sr VP & GM, Consumer Genomics) has filed a Form 3 on ILLUMINA INC |
|
|